MARKET

CLYM

CLYM

Climb Bio
NASDAQ
11.01
+0.72
+7.00%
Pre Market: 10.80 -0.21 -1.91% 04:05 11/10 EST
OPEN
10.49
PREV CLOSE
10.29
HIGH
11.54
LOW
10.28
VOLUME
510
TURNOVER
0
52 WEEK HIGH
18.33
52 WEEK LOW
1.635
MARKET CAP
632.37M
P/E (TTM)
-13.3487
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (GILD), Climb Bio (CLYM) and Legend Biotech (LEGN)
TipRanks · 9h ago
Climb Bio’s Buy Rating Reiterated as Pipeline Catalysts Advance; Price Target Unchanged at $30
TipRanks · 22h ago
Weekly Report: what happened at CLYM last week (1102-1106)?
Weekly Report · 1d ago
Climb Bio Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27
Benzinga · 3d ago
Climb Bio price target raised to $27 from $25 at Wedbush
TipRanks · 3d ago
Climb Bio files automatic mixed securities shelf
TipRanks · 4d ago
Climb Bio Non-GAAP EPS of -$0.18 beats by $0.02
Seeking Alpha · 4d ago
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.